NeuroMetrix Inc. (NSDQ:NURO) faces de-listing from the NASDAQ exchange if it can’t get its stock price back above the exchange’s $1-per-share minimum requirement, according to a regulatory filing.
The Waltham, Mass.-based nerve testing equipment maker’s shares averaged just over 69 cents for the 30 days before the Sept. 24 NASDAQ warning, well below the exchange’s minimum.